title: A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.
abstract: OBJECTIVE
  The efficacy of mesalamine for the maintenance of remission in patients with Crohn's disease is controversial. The aim of this study was to conduct a double-blind, placebo-controlled study of mesalamine (750 mg four times a day for 48 weeks) in maintaining remission in 293 patients with Crohn's disease. Patients were stratified according to the method of induction of remission (medical or surgical).
  
  
  METHODS
  Patients were assessed at weeks 4, 12, 24, 36, and 48. Relapse was defined as a Crohn's Disease Activity Index of >150 (+60 points over baseline).
  
  
  RESULTS
  Of the 293 patients, 246 (84%) returned for at least 4 weeks of follow-up and were included in the final analysis. Thirty of the 118 (25%) who received mesalamine had a relapse compared with 47 of 128 (36%) receiving placebo (P = 0.056). Among those with relapse, the time to relapse was 119 days for the mesalamine-treated patients compared with 109 days for placebo-treated patients (P = NS). However, 25% of mesalamine-treated patients had relapsed by 249 days of follow-up compared with 154 days for placebo-treated patients. Subgroup analysis showed that patients with ileocecal-colonic disease or patients who were women had fewer relapses on mesalamine therapy than placebo-treated patients (21% vs. 41%, P = 0.018; and 19% vs. 41%, P = 0.003, respectively).
  
  
  CONCLUSIONS
  Mesalamine treatment reduced relapse compared with placebo treatment, although conventional statistical significance was not achieved.
authors.affiliation: Department of Medicine and Community Health Sciences, University of Calgary, Alberta, Canada.
authors.forename: L R
authors.initials: LR
authors.lastname: Sutherland
authors.forename: F
authors.initials: F
authors.lastname: Martin
authors.forename: R J
authors.initials: RJ
authors.lastname: Bailey
authors.forename: R N
authors.initials: RN
authors.lastname: Fedorak
authors.forename: M
authors.initials: M
authors.lastname: Poleski
authors.forename: C
authors.initials: C
authors.lastname: Dallaire
authors.forename: R
authors.initials: R
authors.lastname: Rossman
authors.forename: F
authors.initials: F
authors.lastname: Saibil
authors.forename: L
authors.initials: L
authors.lastname: Lariviere
mesh_terms: D000328:Adult; D000636:Aminosalicylic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D019804:Mesalamine; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000636:Aminosalicylic Acids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine